RESEARCH PAPERS - MCAS and Medicines

All Articles Healthcare professionals resources Resources to share with patients Resources for adults Qigong Videos Zoom resources Resources Self-management apps Trigger information RESEARCH PAPERS - MCAS and COVID-19 RESEARCH PAPERS - MCAS and Medicines RESEARCH PAPERS - Clinical Manifestations Research main page ICD-10 categorisation Diagnosis papers Diagnostic tests Patient case examples Wellbeing resources for carers Wellbeing resources for adults Mast Cell Action Brochure Self-management Casper resources Key resources for diagnostic tests Resources for medical professionals MCAS Bibliography Our stories Wellbeing resources Video Presentations by Doctors on MCAS RESEARCH PAPERS – Tests MCAS PATIENT DATA AND DOCUMENTS RESEARCH PAPERS – Diagnosis RESEARCH PAPERS – Comorbidities RESEARCH PAPERS – Treatment RESEARCH PAPERS – Genetics and Pathogenesis

Carbamazepine-induced Stevens-Johnson syndrome in a patient with history of methotrexate-induced mast cell activation syndrome

Zaalouk TM, Bitar ZI, Maadarani OS, Elhabibi ME. Carbamazepine-induced Stevens-Johnson syndrome in a patient with history of methotrexate-induced mast cell activation syndrome. Clin Case Rep. 2020;9(1):256-259. Published 2020 Nov 11. doi:10.1002/ccr3.3509

Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology

Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2019;143(3):880-893. doi:10.1016/j.jaci.2018.10.063

Safe administration of chemotherapy in mast cell activation syndrome

Lythgoe MP, Krell J, McNeish IA, Tookman L. Safe administration of chemotherapy in mast cell activation syndrome. J Oncol Pharm Pract. 2021;27(4):1005-1010. doi:10.1177/1078155220953879

Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome

Schofield JR, Afrin LB. Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome. Am J Med Sci. 2019;357(6):507-511. doi:10.1016/j.amjms.2019.03.005

Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome

Kaakati R, Khokhar D, Akin C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome [published online ahead of print, 2021 May 24]. J Allergy Clin Immunol Pract. 2021;S2213-2198(21)00588-2. doi:10.1016/j.jaip.2021.05.010

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis

Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol. 2021;147(3):877-878. doi:10.1016/j.jaci.2021.01.004

Become a friend

Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives.

Become a friend

Donate

Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.

Make a donation